

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: UCSD-08879

Serial No.: 10/518,181

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Applicant: Judith A. Varner et al.

Filing or 371(c) Date: 9/9/2005

Group Art Unit: 1633

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication Date	Applicant / Patentee	Class	Subclass	Filing Date
	1						
	2						
	3						
	4						
	5						
	6						
	7						
	8						
	9						
	10						

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

/QN/	12	De Rooij <i>et al.</i> (1998) "Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP," Nature 396:474-477
/QN/	13	Amano <i>et al.</i> (2001) "Adenylate cyclase / protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor <i>in vivo</i> ," Jpn. J. Pharmacol. 87:181-188.
	14	
	15	
	16	

Examiner:

/Quang Nguyen/

Date Considered:

02/12/2009

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.